Agonist– tag –
-
Lilly’s Retatrutide Achieves Unprecedented Weight Loss in Pivotal Phase 3 Obesity Trial
Eli Lilly and Company USA Overview Eli Lilly's triple-agonist retatrutide, targeting GIP, GLP-1, and glucagon receptors, demonstrated powerful efficacy in its pivotal Phase 3 TRIUMPH-1 trial for obesity. Patients receiving the highest do... -
Eli Lilly’s Oral Orforglipron Effective in Older Adults with Obesity, Receives FDA Approval as Non-Peptide GLP-1 Offering Dosing Flexibility
Medscape USA Overview Eli Lilly's once-daily oral GLP-1 receptor agonist, orforglipron (Foundayo), demonstrated clinically significant weight loss and a favorable safety profile in obese adults aged 65 and older, similar to younger popul... -
Precision Peptide Company (BPC) Pioneers Advanced Peptide Manufacturing with Continuous Flow Synthesis and AI Integration to Meet GLP-1 Demand
Bitget アイルランド Overview Precision Peptide Company Inc. (BPC) is emerging as a critical CDMO partner for GLP-1 agonists, oncology vaccines, and targeted radiopharmaceuticals. Their proprietary "Flow-Peptide" continuous flow synthesis... -
Novo Nordisk’s CagriSema Achieves Over 22% Weight Loss in Phase 3 Trials: Synergistic Benefits of GLP-1 and Amylin Analog
Life Science Daily News Global Overview Novo Nordisk's CagriSema, a combination therapy featuring a GLP-1 receptor agonist and the amylin analog cagrilintide, demonstrated over 22% weight reduction in Phase 3 trials. Specifically, the RE... -
Divi’s Labs: The ‘TSMC of Pharma’ for Peptides? GLP-1 Demand Elevates Manufacturing to Strategic Imperative
Antifragile Thinking Global Overview The surging global demand for GLP-1 therapeutics has transformed peptide manufacturing into one of the most strategically critical areas within the CDMO sector. India's Divi's Labs stands out as a key... -
Zealand Pharma Advances Obesity Pipeline with Phase 3 Progress, Leveraging Roche and Boehringer Ingelheim Partnerships
WhaleWisdom Global Overview Zealand Pharma, in partnership with Roche, is progressing its obesity drug candidate petrelintide into Phase 3 trials following favorable Phase 2 data on weight loss and tolerability. Separately, Boehringer In... -
CPHI Japan 2026 Highlights Technical Challenges in Peptide Development: GLP-1 Demand Drives Focus on Sustainable Manufacturing
AmbioPharm Japan Overview The CPHI Japan 2026 conference underscored the increasing complexity of peptide drug development and the rising technical expectations for CDMOs. Global demand for GLP-1 agonists is creating a significant bottle... -
Global and Korean Pharma Intensify Race for Next-Gen Oral Obesity Drugs: GLP-1/GIP Dual Agonists and Microneedle Patches Emerge
Chosun Biz South Korea Overview The 2026 European Congress on Obesity highlighted intensified global competition in next-generation oral obesity drug development. Viking Therapeutics announced positive Phase 2 results for its oral GLP-1/...
